ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on April 13, 2026. The report discloses the appointment of a new senior executive officer effective as of the filing date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation.
Material Changes
The primary material change reported is the appointment of Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight joins the company from Crinetics Pharmaceuticals, Inc., where he held the same title from September 2021 to April 2026.
Management Commentary and Compensation Details
In connection with his appointment, Mr. Knight entered into an employment offer letter with the following terms:
- Base Salary: $565,000 annually.
- Cash Bonus: Eligible for an annual target cash bonus equal to 40% of his base salary, contingent on performance objectives.
- Equity Grant: A stock option to purchase 800,000 shares of common stock under the 2025 Inducement Equity Incentive Plan.
- Vesting Schedule: 25% of the option shares vest on the one-year anniversary of the start date, with the remaining shares vesting monthly (1/48th per month) thereafter, subject to continued service.
- Additional Agreements: Mr. Knight has executed a standard change of control and severance agreement and an indemnification agreement.
The filing includes a press release regarding this appointment as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the employment offer letter when filed as an exhibit to a subsequent periodic report.
- Review the standard change of control and severance agreement referenced in the filing (Exhibit 10.12 to the March 9, 2026 Form 10-K).
- Confirm the specific performance objectives required to achieve the 40% target cash bonus.
- Monitor future filings for the impact of the 800,000 share option grant on dilution and equity-based compensation expenses.